Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Director/PDMR Shareholding

27 Jun 2008 15:47

Immediate Release: Friday 27th June 2008

SOPHEON PLC DIRECTORS' SHAREHOLDINGS

Sopheon plc ("Sopheon") announces that it has granted options over Sopheon Ordinary Shares to certain directors as part of a grant of options to certain members of management and staff of the group. The options have been granted at a price of 14.00p per share, being the closing price on 26 June 2008. As part of this grant, Andrew Michuda and Arif Karimjee, being respectively Sopheon's CEO and CFO, have been granted options over 230,000 and 100,000 ordinary shares respectively.

In conjunction with the above grant, certain options previously granted to UK employees have been cancelled and re-issued under a more tax efficient structure. This action includes options that had been granted to Arif Karimjee, comprising options over 200,000 shares at 16.25p granted on 5 November 2003, and options over 100,000 shares at 19.00p granted on 29 June 2007. Apart from the tax basis under which they were granted, all conditions with respect to these options are unchanged from their original basis. Accordingly, the new options have been granted at the original prices of 16.25p and 19.00p respectively.

For further information contact:

Barry Mence, Chairman Sopheon plc + 44 (0) 1483 685 735 Arif Karimjee, CFO Vikki Krause Hansard + 44 (0) 207 245 1100 Communications + 44 (0) 7957 203 685 Claire Verhagen Citigate First + 31 (0) 205 754 010 Financial

Paul Davies, Corporate Finance Seymour Pierce + 44 (0) 207 107 8000 Richard Redmayne, Corpoate

Broking

vendor
Date   Source Headline
24th Jul 20199:05 amRNSSecond Price Monitoring Extn
24th Jul 20199:00 amRNSPrice Monitoring Extension
24th Jul 20197:00 amRNSTrading Update
13th Jun 20191:06 pmRNSResult of AGM
13th Jun 20197:00 amRNSAccolade 12.3
13th Jun 20197:00 amRNSAGM Statement
11th Jun 20191:32 pmRNSIssue of Equity
15th May 20197:00 amRNSSopheon Expands Customer Foothold in Asia
13th May 20199:14 amRNSIssue of Equity
28th Mar 20197:00 amRNSSopheon and National Foods Limited Partnership
21st Mar 20197:00 amRNSFinal Results
5th Feb 20197:00 amRNSIssue of Equity
29th Jan 20197:00 amRNSTrading Update
24th Jan 20194:41 pmRNSSecond Price Monitoring Extn
24th Jan 20194:35 pmRNSPrice Monitoring Extension
17th Jan 20197:00 amRNSAccolade Release 12.2
11th Jan 20197:00 amRNSTrading Update
8th Jan 20197:00 amRNSSopheon Partners with The Hershey Company
18th Dec 20182:53 pmRNSIssue of Equity
16th Nov 201812:54 pmRNSIssue of Equity
31st Oct 20185:18 pmRNSIssue of Equity
23rd Oct 20187:00 amRNSSopheon Awarded The Nature's Bounty Co. Business
8th Oct 20189:05 amRNSSecond Price Monitoring Extn
8th Oct 20189:00 amRNSPrice Monitoring Extension
8th Oct 20187:00 amRNSTrading Update
10th Sep 20187:00 amRNSDoosan Bobcat Awards Sopheon Innovation Contract
7th Sep 20185:48 pmRNSIssue of Equity
29th Aug 20183:54 pmRNSIssue of Equity & Holdings in Company
28th Aug 20187:00 amRNSAccolade Enterprise Innovation Management
23rd Aug 20187:00 amRNSHalf Yearly Report
19th Jul 201811:05 amRNSSecond Price Monitoring Extn
19th Jul 201811:00 amRNSPrice Monitoring Extension
19th Jul 20187:00 amRNSTrading Update
5th Jul 20189:40 amRNSGrant of Options / PDMR Dealing
3rd Jul 20189:24 amRNSIssue of Equity
13th Jun 20182:37 pmRNSIssue of Equity
7th Jun 201812:09 pmRNSResult of AGM
7th Jun 20187:00 amRNSAGM Statement
31st May 20182:56 pmRNSIssue of Equity
17th May 20188:01 amRNSResult of Secondary Placing
16th May 20183:05 pmRNSProposed Secondary Placing
15th May 20187:00 amRNSIssue of Equity
27th Apr 20183:59 pmRNSIssue of Equity
29th Mar 20187:00 amRNSAccolade Release 12.0
23rd Mar 20183:56 pmRNSIssue of Equity
23rd Mar 20187:00 amRNSIssue of Equity
22nd Mar 20187:00 amRNSFinal Results
20th Feb 20187:00 amRNSSopheon named in Annual Reader's Choice List
12th Feb 20189:24 amRNSGrant of Options / PDMR dealing
5th Feb 20183:35 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.